Publications by authors named "Lorenzo Carriera"

The burden of autoimmune diseases is rising worldwide. The expansion of the population of patients eligible for severe asthma biological therapy we are seeing in clinical practice could lead to the simultaneous use of different monoclonal antibodies. We present the case of biological combination therapy with ustekinumab and benralizumab in a patient with ulcerative colitis and severe eosinophilic asthma.

View Article and Find Full Text PDF
Article Synopsis
  • Biological drugs have transformed severe asthma treatment, making remission an achievable goal, while the rise of autoimmune diseases suggests the need for combined therapies.
  • A review of 26 retrospective studies analyzed real-life cases where asthmatic patients also received treatment for other immune-mediated inflammatory diseases (IMIDs) using monoclonal antibodies.
  • The findings highlight the importance of these dual therapies in managing uncontrolled severe asthma, indicating a need for more research to evaluate their safety and effectiveness.
View Article and Find Full Text PDF

Pleural effusion is the most common manifestation of pleural disease, and chest ultrasound is crucial for diagnostic workup and post-treatment monitoring. Ultrasound helps distinguish the various types of pleural effusion and enables the detection of typical manifestations of empyema, which presents as a complicated, septated effusion. This may benefit from drainage and the use of intrapleural enzyme therapy or may require more invasive approaches, such as medical or surgical thoracoscopy.

View Article and Find Full Text PDF

Biological drugs have revolutionized the management of severe asthma. However, a variable number of patients remain uncontrolled or only partially controlled even after the appropriate administration of a biologic agent. The combination of two biologics may target different inflammatory pathways, and it has been used in patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type2 comorbidities.

View Article and Find Full Text PDF